Home Newsfeeds Benchmark Maintains Buy on Lear, Raises Price Target to $170

Benchmark Maintains Buy on Lear, Raises Price Target to $170

Benchmark analyst Michael Ward maintains Lear (NYSE:LEA) with a Buy and raises the price target from $162 to $170.

byBenzinga Newsdesk

January 20, 2023

1 minute read

Benchmark analyst Michael Ward maintains Lear (NYSE:LEA) with a Buy and raises the price target from $162 to $170.

These Analysts Increase Their Forecasts On ZoomInfo After Upbeat Earnings

By Avi Kapoor

February 13, 12:25 PM

ZoomInfo Technologies Inc. (NASDAQ: ZI) reported stronger-than-expected fourth-quarter financial results on Monday.

Analyst Ratings

Expert Ratings For Tandem Diabetes Care

By Benzinga Insights

May 22, 8:00 AM

11 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:TNDM) during the recent three months, expressing a…

TNDM

Nasal-Spray Millionaire: Indivior’s Opvee Nasal Spray Gets FDA Green Light for Opioid Overdose Treatment

By Vandana Singh

May 23, 7:16 AM

The FDA has approved Indivior PLC's (OTC: INVVY) Opvee (nalmefene) nasal spray for the emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older.

EBS

Biden-Xi Talks Continue: Technology Block, Taiwan Top ‘Candid Exchange Of Views’

By Neil Dennis

April 2, 2:44 PM

President Biden and China's President Xi Jinping spoke for the first time since 2023, discussing issues such as trade and national security, including concerns about AI and semiconductor technology.

AMZN

Benchmark Maintains Buy on Lear, Raises Price Target to $170

Related Posts

These Analysts Increase Their Forecasts On ZoomInfo After Upbeat Earnings

Expert Ratings For Tandem Diabetes Care

Nasal-Spray Millionaire: Indivior’s Opvee Nasal Spray Gets FDA Green Light for Opioid Overdose Treatment

Biden-Xi Talks Continue: Technology Block, Taiwan Top ‘Candid Exchange Of Views’